Episurf Hears FDA Feedback on IDE for Episealer Knee

Episurf Medical is entering its next phase for Investigational Device Exemption (IDE) to initiate a U.S. clinical study of the Episealer® knee implant, having submitted its application in mid-2Q18 as planned and now received FDA feedback.

The company has additional details to address prior to setting a finalized IDE study design. “Episurf...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us